HRA Pharma
HRA Pharma is a Paris-founded consumer self-care pharmaceutical company specializing in over-the-counter and women's health products, notably the EllaOne emergency contraception brand. It operates as a subsidiary of Perrigo following the May 2022 acquisition, with rare disease operations divested to Esteve in October 2024.
- Company typePrivate
- Founded1996
- HeadquartersParis, France
- Headcount51–100
- GTM typeB2C
- OfferingHardware or Manufacturing
What HRA Pharma does
HRA Pharma is a Paris-based consumer self-care pharmaceutical company founded in 1996 that develops and markets over-the-counter medicines and prescription equivalents for conditions consumers can self-manage, with particular specialization in women's health and reproductive health. Its flagship product is EllaOne, an emergency contraception brand supported by dedicated patient information documentation. The company operated a distinct rare diseases division (HRA Pharma Rare Diseases) covering specialized therapeutic areas. Prior to 2022, HRA Pharma was an independent privately-held entity that raised capital from investors including Riverside Company, Astorg, and Goldman Sachs.
In May 2022, Perrigo Company plc (NYSE: PRGO) completed the acquisition of HRA Pharma, integrating the company's branded self-care portfolio into Perrigo's global consumer self-care organization and leveraging Perrigo's retail and pharmacy distribution network across 20+ countries. In October 2024, Perrigo divested the HRA Pharma Rare Diseases business to Spain-based Esteve Pharmaceuticals S.A., separating rare disease operations from the core consumer self-care franchise. The leadership team includes a CEO, CFO, Chief Scientific Officer, Chief Global Commercial Officer, Chief Human Resources & Communication Officer, and Chief Corporate Development & Strategy Officer, and headcount is reported in the 51-100 range. HRA Pharma's business model is product sales of consumer pharmaceutical brands through retail and pharmacy channels; revenue mechanics now flow through Perrigo's global distribution infrastructure rather than direct-to-consumer channels.
HRA Pharma firmographics
Firmographics- Name
- HRA Pharma
- Legal name
- HRA Pharma
- Website
- https://hra-pharma.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- HRA Pharma is a Paris-founded consumer self-care pharmaceutical company specializing in over-the-counter and women's health products, notably the EllaOne emergency contraception brand. It operates as a subsidiary of Perrigo following the May 2022 acquisition, with rare disease operations divested to Esteve in October 2024.
- Ownership category
- akta.pro rank
HRA Pharma industry classification
Industry- Product category
- Consumer Pharmaceuticals (Women's Health)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)
- akta.pro secondary industries
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where HRA Pharma is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Markets served
HRA Pharma business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel
Revenue model
- Consumer Self-Care Products: HRA Pharma developed and marketed consumer self-care pharmaceutical products, including over-the-counter medicines and prescription equivalents for conditions that can be self-managed.
Distribution channels1 record
Marketing channels1 record
HRA Pharma product offering
Product offeringCore offering
HRA Pharma develops, manufactures, and markets consumer self-care pharmaceutical products focused on women's health and reproductive health. Its primary offering is EllaOne, an emergency contraception product sold over the counter. The company also operated a rare diseases division (divested to Esteve Pharmaceuticals in October 2024). Following Perrigo's May 2022 acquisition, HRA Pharma products are distributed through Perrigo's global retail and pharmacy channel network.
Product overview
HRA Pharma is a pharmaceutical company that was part of Perrigo's consumer self-care portfolio following the May 2022 acquisition. The company specializes in consumer health products and had a rare diseases division. Notable products include EllaOne (emergency contraception). In October 2024, Esteve Pharmaceuticals acquired HRA Pharma Rare Diseases from Perrigo. The product portfolio spans women's health and other consumer healthcare categories.
Differentiator
Problem solved
Functional benefit
Products and services
- EllaOne EllaOne is HRA Pharma's emergency contraception consumer pharmaceutical product, distributed over the counter through retail pharmacies and healthcare outlets across Perrigo's international markets, and supported by published Patient Information Leaflet (PIL) documentation for consumers.
- HRA Pharma Consumer Self-Care Product Portfolio HRA Pharma's consumer self-care product portfolio spans women's health, including emergency contraception and other reproductive self-care pharmaceutical products, and is distributed across Europe and other international markets through Perrigo's regional pharmacy and retail outlet network.
Companies that use HRA Pharma
Customer profileSegments1 record
Ideal customer profiles2 records
HRA Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HRA Pharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Esteve Pharmaceuticals S.A.coreIn October 2024, Esteve Pharmaceuticals S.A. (Spain) acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed sum. This transaction strengthened Esteve's rare disease portfolio and international expansion capabilities.
- Perrigo Company plccorePerrigo Company plc (NYSE: PRGO) completed the acquisition of HRA Pharma on May 02, 2022. HRA Pharma became part of Perrigo's consumer self-care product portfolio under the corporate structure at https://www.perrigo.com/hra-pharma.
Scale indicators2 records
Recent moves5 records
Expansion highlights4 records
HRA Pharma competitors and assessment
Company assessmentDirect peers
- Organon & Co. Public women's health-focused pharmaceutical company spun out of Merck, with a portfolio spanning contraception, fertility, and reproductive health. Directly comparable to HRA Pharma as a branded specialty pharma anchored in women's reproductive health consumer products.
- TherapeuticsMD: US-listed women's health pharmaceutical company commercializing branded prescription products in contraception, hormone therapy, and prenatal care. Comparable to HRA Pharma in its branded women's health go-to-market model and reliance on differentiated reproductive health products.
- Exeltis: Global women's health specialty pharmaceutical company offering branded generics and innovative products across contraception, fertility, and maternal health. Comparable to HRA Pharma in focus, channel (pharmacy and consumer), and women's health self-care orientation.
Broad incumbents
- Bayer AG (Women's Health / Consumer Health): Diversified global life sciences company whose Consumer Health division includes leading women's health and reproductive products. Comparable to HRA Pharma as a large incumbent competing across women's health and consumer self-care categories with overlapping products such as oral contraceptives.
- Pfizer Inc. (Women's Health portfolio): Major global pharmaceutical company with a women's health franchise including contraceptive and reproductive therapies. Comparable as a broad incumbent that competes with HRA Pharma in reproductive health while operating at significantly greater scale.
- Lupin Pharmaceuticals: Large Indian-headquartered generics and specialty pharmaceutical company with a women's health portfolio including oral contraceptives. Comparable as a broad incumbent competing in women's reproductive health and consumer self-care categories across multiple geographies.
Emerging players
- Agile Therapeutics: Smaller US-focused women's health company developing branded hormonal contraceptive products. Comparable to HRA Pharma as a niche branded player in women's reproductive health, though materially smaller and concentrated in the US market.
- Evofem Biosciences: Women's health biotech commercializing branded contraceptives and sexual health products. Comparable to HRA Pharma as a smaller specialized reproductive health player competing in contraception and women's preventive health.
- CooperSurgical: Women's health-focused medical device and fertility company providing products across reproductive and contraceptive care. Comparable to HRA Pharma in the broader women's reproductive health category, though more focused on devices and fertility services than consumer pharma.
- Myovant Sciences (Sumitomo Pharma): Women's health and prostate cancer focused biopharmaceutical company, now a subsidiary of Sumitomo Pharma. Comparable to HRA Pharma in its branded women's reproductive health focus, particularly uterine health and hormonal therapies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
HRA Pharma social profiles
Digital presenceHRA Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
HRA Pharma leadership team
Management profileNumber of profiles
Profiles6 records
HRA Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HRA Pharma M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HRA Pharma
What does HRA Pharma do?
HRA Pharma develops, manufactures, and markets consumer self-care pharmaceutical products focused on women's health and reproductive health. Its primary offering is EllaOne, an emergency contraception product sold over the counter. The company also operated a rare diseases division (divested to Esteve Pharmaceuticals in October 2024). Following Perrigo's May 2022 acquisition, HRA Pharma products are distributed through Perrigo's global retail and pharmacy channel network.
Is HRA Pharma a public or private company?
HRA Pharma is a private company. It is classified as corporate owned and is currently acquired.
When was HRA Pharma founded?
HRA Pharma was founded in 1996. It employs 51 to 100 people.
Where is HRA Pharma based?
HRA Pharma is headquartered in Paris, France, in the Europe region.
How does HRA Pharma make money?
One revenue line is on record: consumer Self-Care Products.
Who are HRA Pharma's main competitors?
Direct peers on record are Organon & Co., TherapeuticsMD and Exeltis. Broad incumbents are Bayer AG (Women's Health / Consumer Health), Pfizer Inc. (Women's Health portfolio) and Lupin Pharmaceuticals. Emerging players are Agile Therapeutics, Evofem Biosciences, CooperSurgical and Myovant Sciences (Sumitomo Pharma).
Does HRA Pharma have an API?
No public API is recorded for HRA Pharma.
What industry is HRA Pharma in?
HRA Pharma's product category is Consumer Pharmaceuticals (Women's Health). Its primary akta.pro industry code is HLAIACAN, Women’s Health & Reproductive Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.